Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Top Cited Papers
- 31 August 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10200), 737-745
- https://doi.org/10.1016/S0140-6736(19)31606-X
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating MigraineJournal of Medicinal Chemistry, 2012
- Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache FeaturesHeadache: The Journal of Head and Face Pain, 2012
- BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II studyCephalalgia, 2010
- Why pharmacokinetic differences among oral triptans have little clinical importance: a commentThe Journal of Headache and Pain, 2010
- Headache and migraine in primary care: consultation, prescription, and referral rates in a large populationJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of MigraineNew England Journal of Medicine, 2004
- Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?Headache: The Journal of Head and Face Pain, 1999
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnnals of Neurology, 1988